A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus
A phase 1/2 trial of Tislelizumab in colorectal cancer, run by BeiGene, active and no longer recruiting.
Overview
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05609370 by BeiGene, with 113 participants enrolled, started 2023-01-29 and due to reach its primary completion in 2025-05-23. Interventions recorded: Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP). Conditions listed: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
- TrialA Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants
- TrialRATIONALE-302
- TrialA Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
- PersonJie Wang
- TrialA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol
- TrialStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
- TrialStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Shares Tislelizumab, Colorectal cancer.